Lexicon Pharmaceuticals, Inc. (LXRX) is a fully integrated biopharmaceutical company that is focused on discovering, developing and commercializing breakthrough treatments for diseases with significant unmet medical needs. Founded in 1995 and headquartered in The Woodlands, Texas, the company leverages its proprietary gene knockout technologies to discover novel drug targets.
The mission of Lexicon Pharmaceuticals is to transform the lives of patients by integrating advanced technologies to decode the functions of genes to discover and develop innovative drug therapies. The company has a commitment to novel science and innovative trail design that aims to achieve the broadest impact for patients.
Lexicon Pharmaceuticals has made significant advances in their drug discovery and development programs, with two marketed products. Their first product LX4211 (sotagliflozin), developed as a first-in-class treatment for Type 1 diabetes, was approved by the European Commission in 2019. Their second drug, Xermelo (telotristat ethyl) is used for the treatment of carcinoid syndrome diarrhea in cancer patients with metastatic neuroendocrine tumors and is approved in more than 40 countries.
The company’s drug discovery efforts are supported by a refined genomic approach, which has allowed them to prioritize therapeutic areas with major unmet medical needs, such as diabetes and carcinoid syndrome. This data-driven approach is pivotal in their strategy to advance promising compounds into preclinical and clinical development.
Lexicon Pharmaceuticals invests significantly in research and development, dedicating a major portion of their expenses to it. This affirms their commitment to innovation and continuous expansion of their pipeline. With its dedication to forward-thinking patient-centric solutions, Lexicon Pharmaceuticals has the potential to bring unprecedented change in the lives of patients suffering from serious diseases.
The company has a strong corporate culture that integrates emphasis on technological innovation, strategic development, and a passion for helping patients. Lexicon Pharmaceuticals believes its technology and approach will ensure a steady stream of new products that stand out in the competitive biopharmaceutical market.
A noteworthy aspect of the company is their commitment to leadership ethics, transparency and corporate governance. This is manifested through various policies and procedures that ensure integrity, compliance and credibility in all their dealings.
With its expertise and capabilities, Lexicon Pharmaceuticals is poised to make meaningful contributions to the healthcare industry and ultimately, patient’s lives. This makes LXRX a dynamic entity in the biopharmaceutical sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Lexicon Pharmaceuticals (LXRX) is highlighted as a strong buy due to its advancing cardiometabolic franchise, particularly with its drug sotagliflozin (Inpefa), which is expanding into new indications like hypertrophic cardiomyopathy and type 1 diabetes. The company also benefits from a significant licensing agreement with Novo Nordisk for its obesity asset LX9851 and is progressing with pilavapadin for neuropathic pain. These developments, along with its recent stock performance, suggest a period of potential growth for LXRX.
Lexicon Pharmaceuticals announced its management will present at three upcoming investor conferences in New York, NY. The conferences include the Citi 2026 Biopharma Back to School Conference, the 2026 Cantor Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference, all taking place in September 2026. The company, a biopharmaceutical firm focused on pioneering medicines for various conditions, will make live presentations and offer replays via its investor relations website.
Lexicon Pharmaceuticals has received a third $10 million milestone payment from Novo Nordisk after achieving a key patient dosing milestone in the Phase 1 clinical development program for LX9851. This payment brings Lexicon's total earnings from the collaboration to $75 million out of a potential $1 billion. LX9851 is a first-in-class oral small molecule inhibitor being developed by Novo Nordisk for obesity and associated metabolic disorders, with the Phase 1 program expected to conclude in Q1 2027.
Lexicon Pharmaceuticals (LXRX) reported a significant deterioration in its Q2 2026 results, with revenue dropping to US$692,000 from US$28.87 million year-over-year, and shifting from a net income of US$3.25 million to a net loss of US$31.78 million. This performance highlights the company's increased dependence on licensing income, future milestones, and external funding, especially as it awaits Phase 3 trial data for sotagliflozin in early 2027. The article suggests that this sharp downturn could alter the investment narrative for Lexicon, emphasizing the critical need for successful trial outcomes and securing funding.
Lexicon Pharmaceuticals (LXRX) reported a significant deterioration in its Q2 2026 operating performance, with revenue plummeting to US$692,000 from US$28.87 million a year earlier, and a net loss of US$31.78 million replacing a prior net income. This sharp decline in revenue and shift to a wider loss is expected to impact the company's investment narrative, highlighting its increased reliance on licensing income, trial progress, and future milestones. The article emphasizes that Lexicon's future depends heavily on its cardiometabolic and pain pipeline, particularly the SONATA HCM Phase 3 trial for sotagliflozin, with top-line data anticipated in early 2027.